JP7684315B2 - トリスルフィド化合物及びその包接体 - Google Patents

トリスルフィド化合物及びその包接体 Download PDF

Info

Publication number
JP7684315B2
JP7684315B2 JP2022545682A JP2022545682A JP7684315B2 JP 7684315 B2 JP7684315 B2 JP 7684315B2 JP 2022545682 A JP2022545682 A JP 2022545682A JP 2022545682 A JP2022545682 A JP 2022545682A JP 7684315 B2 JP7684315 B2 JP 7684315B2
Authority
JP
Japan
Prior art keywords
group
trisulfide
carbon atoms
cyclodextrin
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022545682A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022045212A1 (https=
Inventor
昌一郎 朝長
貴弘 磯部
悦男 大島
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Pharma Chemical Co Ltd
Original Assignee
Kyowa Pharma Chemical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Pharma Chemical Co Ltd filed Critical Kyowa Pharma Chemical Co Ltd
Publication of JPWO2022045212A1 publication Critical patent/JPWO2022045212A1/ja
Application granted granted Critical
Publication of JP7684315B2 publication Critical patent/JP7684315B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D341/00—Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2022545682A 2020-08-27 2021-08-25 トリスルフィド化合物及びその包接体 Active JP7684315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020143645 2020-08-27
JP2020143645 2020-08-27
PCT/JP2021/031222 WO2022045212A1 (ja) 2020-08-27 2021-08-25 トリスルフィド化合物及びその包接体

Publications (2)

Publication Number Publication Date
JPWO2022045212A1 JPWO2022045212A1 (https=) 2022-03-03
JP7684315B2 true JP7684315B2 (ja) 2025-05-27

Family

ID=80355339

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022545682A Active JP7684315B2 (ja) 2020-08-27 2021-08-25 トリスルフィド化合物及びその包接体

Country Status (5)

Country Link
US (1) US12552764B2 (https=)
EP (1) EP4194448A4 (https=)
JP (1) JP7684315B2 (https=)
CN (1) CN115989026A (https=)
WO (1) WO2022045212A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7842033B2 (ja) 2020-05-12 2026-04-07 ザ ジェネラル ホスピタル コーポレイション 神経保護におけるグルタチオントリスルフィド（ｇｓｓｓｇ）
EP4342464A4 (en) 2021-07-08 2025-06-04 Kyowa Pharma Chemical Co., Ltd. PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PARKINSON'S DISEASE
TW202321270A (zh) * 2021-09-09 2023-06-01 國立大學法人九州大學 使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法
EP4603087A1 (en) 2022-11-21 2025-08-20 Kyowa Hakko Bio Co., Ltd. Prophylactic or therapeutic agent for acute kidney injury induced by anticancer agent
CN115716817B (zh) * 2022-11-22 2024-04-19 国药集团威奇达药业有限公司 6,8-环三硫辛酸的制备方法
CN120390743A (zh) 2022-12-27 2025-07-29 协和医药化工股份有限公司 三硫化物化合物及其包合物
EP4647072A1 (en) 2023-03-07 2025-11-12 Kyowa Hakko Bio Co., Ltd. Enhancer of physiological activity of hepatocyte growth factor
WO2025028521A1 (ja) 2023-08-01 2025-02-06 キリンホールディングス株式会社 肝機能障害の予防又は改善用組成物
WO2025070464A1 (ja) 2023-09-28 2025-04-03 協和ファーマケミカル株式会社 トリスルフィド化合物を含有する医薬組成物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530866A (ja) 2002-05-10 2005-10-13 雲清 劉 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法
CN101607955A (zh) 2008-06-18 2009-12-23 上海津力化工有限公司 一种低残留硫辛酸的制备方法
CN107652264A (zh) 2017-09-25 2018-02-02 苏州华诺医药有限公司 硫辛酸杂质a的制备方法
JP2019534864A (ja) 2016-09-23 2019-12-05 アンコール ビジョン， インコーポレイテッド リポ酸コリンエステル組成物及び医薬的に適切な製剤中で安定化させる方法
CN111320603A (zh) 2018-12-13 2020-06-23 江苏同禾药业有限公司 一种硫辛酸工艺杂质的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS377970B1 (https=) 1959-12-08 1962-07-11
DE4338508A1 (de) 1993-11-11 1995-05-18 Asta Medica Ag Arzneimittelzubereitungen enthaltend Thioctsäure oder Dihydroliponsäure in Form von Einschlußverbindungen mit Cyclodextrinen oder Cyclodextrinderivaten und in Form von Granulaten, Kau- oder Brausetabletten
EP1707217A1 (en) * 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
EP4342464A4 (en) * 2021-07-08 2025-06-04 Kyowa Pharma Chemical Co., Ltd. PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PARKINSON'S DISEASE

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530866A (ja) 2002-05-10 2005-10-13 雲清 劉 有機医薬とβ−シクロデキストリン誘導体との複合体、およびその調製方法
CN101607955A (zh) 2008-06-18 2009-12-23 上海津力化工有限公司 一种低残留硫辛酸的制备方法
JP2019534864A (ja) 2016-09-23 2019-12-05 アンコール ビジョン， インコーポレイテッド リポ酸コリンエステル組成物及び医薬的に適切な製剤中で安定化させる方法
CN107652264A (zh) 2017-09-25 2018-02-02 苏州华诺医药有限公司 硫辛酸杂质a的制备方法
CN111320603A (zh) 2018-12-13 2020-06-23 江苏同禾药业有限公司 一种硫辛酸工艺杂质的制备方法

Also Published As

Publication number Publication date
CN115989026A (zh) 2023-04-18
US20230331692A1 (en) 2023-10-19
EP4194448A1 (en) 2023-06-14
US12552764B2 (en) 2026-02-17
WO2022045212A1 (ja) 2022-03-03
JPWO2022045212A1 (https=) 2022-03-03
EP4194448A4 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
JP7684315B2 (ja) トリスルフィド化合物及びその包接体
CN115943140B (zh) 三硫化物化合物
EP2081965A1 (fr) Procede de preparation d'oligomeres ou polymeres de cyclodextrines, produits obtenus et utilisations
KR20030078117A (ko) 푸마질롤 유도체 또는 그 염의 포접 화합물, 및 이를포함하는 약제학적 조성물
IE922234A1 (en) Process for the preparation of derivatives of baccatin III and of 10-deacetylbaccatin III
JP7659282B2 (ja) トリスルフィド化合物を用いる、肝細胞増殖因子中のチロシン残基のニトロ化を防止する方法
KR101128450B1 (ko) 안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
FR2714067A1 (fr) Nouveaux dérivés de cyclodextrines, utilisables en particulier pour solubiliser des composés chimiques hydrophobes tels que des médicaments, et leur procédé de préparation.
CN117320709A (zh) 帕金森病的预防或治疗药
EP4613743A1 (en) Trisulfide compound and clathrate thereof
EP0886654B1 (fr) Thioureido-cyclodextrines, utilisables en particulier pour solubiliser des agents antitumoraux et antiparasitaires et leurs procedes de preparation
EP0735879B1 (fr) Utilisation de cyclodextrines aminees pour la solubilisation aqueuse des dibenzazepines utilisables comme agent anti-epileptique
JPS6036490A (ja) 水溶性リフアンピシン誘導体
WO1995019994A1 (fr) Procede de solubilisation dans un milieu aqueux d'agents antitumoraux de la famille du taxol, et cyclodextrines ramifiees utilisables pour cette solubilisation
WO2024143400A1 (ja) トリスルフィド化合物
ES2332285T3 (es) Procedimiento para la preparacion de ziprasidona.
KR20050105565A (ko) 저장안정성이 우수한 벤즈이미다졸 유도체 함유 포접복합체 및 이의 제조방법
EP4714441A1 (en) Composition for preventing or alleviating hepatic dysfunction
KR20070069567A (ko) 저장안정성이 우수한 ｓ-오메프라졸 함유 포접 복합체 및이의 제조방법
WO2024230717A1 (zh) 抗真菌药的载药大分子及其制备方法
WO2026058944A1 (ja) 非対称型のトリスルフィド化合物
FR2806929A1 (fr) Nouveaux supports chromatographiques a base de cyclodextrines, leur procede de preparation et leurs applications
WO2013110796A1 (fr) Dérivés de thiazolidinedione, leur préparation et leur utilisation dans le traitement des cancers
FR2781800A1 (fr) Derives de 2-aminoethyl-benzofurane et de 2-aminoethyl-benzothiophene, leurs preparations et leurs applications en therapeutique

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240816

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250507

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250515

R150 Certificate of patent or registration of utility model

Ref document number: 7684315

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150